Copyright in the material you requested is held by American College Of Physicians
(unless otherwise noted). This email ability is provided as a courtesy, and by using
it you agree that that you are requesting the material solely for personal, non-commercial
use, and that it is subject to ACP's Conditions of Use.
The information provided in order to email this topic will not be used to send unsolicited
email, nor will it be furnished to third parties. Please refer to
American College Of Physicians'sPrivacy
Policy for further information.

Cyclophosphamide To Treat Patients with Scleroderma Lung DiseaseFREE

The summary below is from the full report titled “Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis.” It is in the 20 June 2000 issue of Annals of Internal Medicine (volume 132, pages 947-954). The authors are B. White, W.C. Moore, F.M. Wigley, H.Q. Xiao, and R.A. Wise.

What is the problem and what is known about it so far?

Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. This results in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, kidneys, and digestive tract. Scleroderma lung disease is difficult to treat. Lung inflammation (alveolitis) occurs before lung scarring (fibrosis). Cyclophosphamide is a drug that decreases inflammation; therefore, it may be useful in treating patients with scleroderma lung disease.

Why did the researchers do this particular study?

To find out whether patients with scleroderma lung disease who receive cyclophosphamide have better lung function and live longer than patients who do not get this drug.

Who was studied?

The researchers studied 103 patients with scleroderma lung disease at the Johns Hopkins and University of Maryland Scleroderma Center.

How was the study done?

Some of the patients were treated with cyclophosphamide, depending on their doctor's decision. All of the patients underwent procedures to obtain pieces of lung tissue (biopsies) or lung cells (washings) that could be examined for inflammation. The researchers looked for signs of alveolitis on the lung biopsies or washings. They then compared lung function, which they evaluated by using special breathing tests, and survival among patients who got cyclophosphamide and patients who did not get this drug.

What did the researchers find?

Of the 103 patients, 69 had alveolitis and 34 did not. Thirty-nine of the patients with alveolitis got cyclophosphamide and 30 did not. Patients with alveolitis who got cyclophosphamide did better on the breathing tests and survived longer than those who did not get the drug. Side effects of cyclophosphamide treatment included hair loss, infection, and bleeding into the urinary tract.

What were the limitations of the study?

Patients were not randomly assigned to get or to not get cyclophosphamide. It is possible, therefore, that the doctors may have given the drug to the patients who had the best chances of doing well. Also, there were too few patients to be able to identify which types of patients with scleroderma lung disease were most likely to benefit from treatment with cyclophosphamide.

What are the implications of the study?

Patients with scleroderma lung disease involving inflammation of the lungs who get cyclophosphamide appear to have improvements in their breathing and live longer than similar patients who do not get this drug.

Comments

Please read the other comments before posting. Contributors must reveal any conflict
of interest.
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.

* = Required Field

Comment Author(s)* (if multiple authors,
separate names by comma)

Example: John Doe

Affiliation & Institution*

Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.